Ch
China Biologic
Beijing CNFounded 20024,000 employees
Private CapbiotechAcquiredHematology
Platform: Plasma-derived
Market Cap
N/A
All Drugs
4
Clinical Trials
8
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| CHI-3542 | CHI-3542 | Phase 2 | 2 | CD19 | HNSCCBreast Ca | ||
| Nidazumab | CHI-4324 | Phase 1 | 2 | CD38 | PSPPsA | ||
| Capisertib | CHI-3523 | NDA/BLA | 2 | PD-1 | ObesityUC | ||
| CHI-1577 | CHI-1577 | Phase 2/3 | 2 | HER2 | MigraineNarcolepsy |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (8)